Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA issues second CRL for AZ's hyperkalemia candidate

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it received a second complete response letter from FDA for ZS-9, its candidate

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE